Persistent Lyme Empiric Antibiotic Study Europe (PLEASE) - Design of a randomized controlled trial of prolonged antibiotic treatment in patients with persistent symptoms attributed to Lyme borreliosis

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Berende, Anneleen ^a   ter Hofstede, Hadewych J M ^a   Rogier T Donders, A ^a   van Middendorp, Henriët ^a,b   Kessels, Roy P C ^a,c   Adang, Eddy M M ^a   Vos, Fidel J ^a,d   Evers, Andrea W M ^a,b   Kullberg, Bart Jan ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

^c RADBOUD UNIVERSITY   (Netherlands)

^d SINT MAARTENSKLINIEK   (Netherlands)

Author keywords

Borreliosis; Clarithromycin; Doxycycline; Guidelines; Hydroxychloroquine; Lyme disease; Persistent symptoms; Placebo; Study protocol; Treatment

Indexed keywords

ASTEMIZOLE; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; CEFTRIAXONE; CISAPRIDE; CLARITHROMYCIN; DOXYCYCLINE; HEMOPOIETIC GROWTH FACTOR; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PHENYTOIN; PLACEBO; PREDNISONE; RECOMBINANT CYTOKINE; TERFENADINE; ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BORRELIA BURGDORFERI; BORRELIA INFECTION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOUBLE BLIND PROCEDURE; ERYTHEMA CHRONICUM MIGRANS; FATIGUE; FEMALE; FOLLOW UP; HUMAN; IMMUNOBLOTTING; LONG TERM CARE; LYME DISEASE; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHOLOGY; PHYSICAL ACTIVITY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; SHORT FORM 36; DRUG ADMINISTRATION; EUROPE; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; ANTI-BACTERIAL AGENTS; BORRELIA BURGDORFERI; CEFTRIAXONE; DOUBLE-BLIND METHOD; DOXYCYCLINE; DRUG ADMINISTRATION SCHEDULE; EUROPE; FEMALE; HUMANS; HYDROXYCHLOROQUINE; LYME DISEASE; MALE; TREATMENT OUTCOME;

EID: 84964313259     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-014-0543-y     Document Type: Article

References (62)

1. Bacon RM, Kugeler KJ, Mead PS, Centers for Disease Control and Prevention (CDC): Surveillance for Lyme disease-United States, 1992-2006. MMWR Surveill Summ 2008, 57:1-9.
2. CDC Lyme Disease Statistics. [http://www.cdc.gov/lyme/stats/]
3. Heyman P, Cochez C, Hofhuis A, van der Giessen J, Sprong H, Porter SR, Losson B, Saegerman C, Donoso-Mantke O, Niedrig M, Papa A: A clear and present danger: tick-borne diseases in Europe. Expert Rev Anti Infect Ther 2010, 8:33-50.
4. Hofhuis A, Harms MG, van der Giessen JWB, Sprong H, Notermans DW, van Pelt W: Ziekte van Lyme in Nederland 1994-2009: Aantal huisartsconsulten blijft toenemen. Is voorlichting en curatief beleid genoeg? Infectieziekten Bull 2010, 21:84-87.
5. Hofhuis A, van der Giessen JW, Borgsteede FH, Wielinga PR, Notermans DW, van Pelt W: Lyme borreliosis in the Netherlands: strong increase in GP consultations and hospital admissions in past 10 years. Euro Surveill 2006, 11:E060622-060622.
6. Donta ST: Late and chronic Lyme disease. Med Clin North Am 2002, 86:341-349. vii.
7. Shadick NA, Phillips CB, Sangha O, Logigian EL, Kaplan RF, Wright EA, Fossel AH, Fossel K, Berardi V, Lew RA, Liang MH: Musculoskeletal and neurologic outcomes in patients with previously treated Lyme disease. Ann Intern Med 1999, 131:919-926.
8. Cairns V, Godwin J: Post-Lyme borreliosis syndrome: a meta-analysis of reported symptoms. Int J Epidemiol 2005, 34:1340-1345.
9. Wormser GP, Ramanathan R, Nowakowski J, McKenna D, Holmgren D, Visintainer P, Dornbush R, Singh B, Nadelman RB: Duration of antibiotic therapy for early Lyme disease. A randomized, double-blind, placebocontrolled trial. Ann Intern Med 2003, 138:697-704.
10. Klempner MS, Hu LT, Evans J, Schmid CH, Johnson GM, Trevino RP, Norton D, Levy L, Wall D, McCall J, Kosinski M, Weinstein A: Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med 2001, 345:85-92.
11. Wormser GP, Dattwyler RJ, Shapiro ED, Halperin JJ, Steere AC, Klempner MS, Krause PJ, Bakken JS, Strle F, Stanek G, Bockenstedt L, Fish D, Dumler JS, Nadelman RB: The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006, 43:1089-1134.
12. Feder HM Jr, Gerber MA, Luger SW, Ryan RW: Persistence of serum antibodies to Borrelia burgdorferi in patients treated for Lyme disease. Clin Infect Dis 1992, 15:788-793.
13. Berglund J, Eitrem R, Norrby SR: Long-term study of Lyme borreliosis in a highly endemic area in Sweden. Scand J Infect Dis 1996, 28:473-478.
14. Kuiper H, de Jongh BM, Nauta AP, Houweling H, Wiessing LG, van Charante AW, Spanjaard L: Lyme borreliosis in Dutch forestry workers. J Infect 1991, 23:279-286.
15. Wormser GP, Nadelman RB, Dattwyler RJ, Dennis DT, Shapiro ED, Steere AC, Rush TJ, Rahn DW, Coyle PK, Persing DH, Fish D, Luft BJ: Practice guidelines for the treatment of Lyme disease. The Infectious Diseases Society of America. Clin Infect Dis 2000, 31(1):1-14.
16. Cameron D, Gaito A, Harris N, Bach G, Bellovin S, Bock K, Bock S, Burrascano J, Dickey C, Horowitz R, Phillips S, Meer-Scherrer L, Raxlen B, Sherr V, Smith H, Smith P, Stricker R, Group IW: Evidence-based guidelines for the management of Lyme disease. Expert Rev Anti Infect Ther 2004, 2:S1-S13.
17. Krupp LB, Hyman LG, Grimson R, Coyle PK, Melville P, Ahnn S, Dattwyler R, Chandler B: Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial. Neurology 2003, 60:1923-1930.
18. Cameron D: Severity of Lyme disease with persistent symptoms. Insights from a double-blind placebo-controlled clinical trial. Minerva Med 2008, 99:489-496.
19. Delong AK, Blossom B, Maloney EL, Phillips SE: Antibiotic retreatment of Lyme disease in patients with persistent symptoms: a biostatistical review of randomized, placebo-controlled, clinical trials. Contemp Clin Trials 2012, 33:1132-1142.
20. Stanek G, O'Connell S, Cimmino M, Aberer E, Kristoferitsch W, Granstrom M, Guy E, Gray J: European Union Concerted Action on Risk Assessment in Lyme Borreliosis: clinical case definitions for Lyme borreliosis. Wien Klin Wochenschr 1996, 108:741-747.
21. Hauser U, Lehnert G, Wilske B: Validity of interpretation criteria for standardized Western blots (immunoblots) for serodiagnosis of Lyme borreliosis based on sera collected throughout Europe. J Clin Microbiol 1999, 37:2241-2247.
22. Hays RD: Rand-36 Health Status Inventory. San Antonio: The Psychological Corporation; 1998.
23. Hugen PW, Langebeek N, Burger DM, Zomer B, van Leusen R, Schuurman R, Koopmans PP, Hekster YA: Assessment of adherence to HIV protease inhibitors: comparison and combination of various methods, including MEMS (electronic monitoring), patient and nurse report, and therapeutic drug monitoring. J Acquir Immune Defic Syndr 2002, 30:324-334.
24. Urquhart J: The electronic medication event monitor. Lessons for pharmacotherapy. Clin Pharmacokinet 1997, 32:345-356.
25. Ljostad U, Skogvoll E, Eikeland R, Midgard R, Skarpaas T, Berg A, Mygland A: Oral doxycycline versus intravenous ceftriaxone for European Lyme neuroborreliosis: a multicentre, non-inferiority, double-blind, randomised trial. Lancet Neurol 2008, 7:690-695.
26. Vercoulen JH, Swanink CM, Fennis JF, Galama JM, van der Meer JW, Bleijenberg G: Dimensional assessment of chronic fatigue syndrome. J Psychosom Res 1994, 38:383-392.
27. Evers AW, Kraaimaat FW, van Riel PL, de Jong AJ: Tailored cognitivebehavioral therapy in early rheumatoid arthritis for patients at risk: a randomized controlled trial. Pain 2002, 100:141-153.
28. Evers AW, Taal E, Kraaimaat FW, Jacobs JW, Abdel-Nasser A, Rasker JJ, Bijlsma JW: A comparison of two recently developed health status instruments for patients with arthritis: Dutch-AIMS2 and IRGL. Arthritis Impact Measurement Scales. Impact of Rheumatic diseases on General health and Lifestyle. Br J Rheumatol 1998, 37:157-164.
29. Fallon BA, Keilp JG, Corbera KM, Petkova E, Britton CB, Dwyer E, Slavov I, Cheng J, Dobkin J, Nelson DR, Sackeim HA: A randomized, placebocontrolled trial of repeated IV antibiotic therapy for Lyme encephalopathy. Neurology 2008, 70:992-1003.
30. Kaplan RF, Trevino RP, Johnson GM, Levy L, Dornbush R, Hu LT, Evans J, Weinstein A, Schmid CH, Klempner MS: Cognitive function in posttreatment Lyme disease: do additional antibiotics help? Neurology 2003, 60:1916-1922.
31. Van der Elst W, van Boxtel MP, van Breukelen GJ, Jolles J: Rey's verbal learning test: normative data for 1855 healthy participants aged 24-81 years and the influence of age, sex, education, and mode of presentation. J Int Neuropsychol Soc 2005, 11:290-302.
32. Wechsler D: Wechsler Adult Intelligence Scale. 3rd edition. San Antonio, TX: Psychological Corporation; 1997.
33. Van der Elst W, Van Boxtel MP, Van Breukelen GJ, Jolles J: Normative data for the Animal, Profession and Letter M Naming verbal fluency tests for Dutch speaking participants and the effects of age, education, and sex. J Int Neuropsychol Soc 2006, 12:80-89.
34. Bowie CR, Harvey PD: Administration and interpretation of the Trail Making Test. Nat Protoc 2006, 1:2277-2281.
35. Van der Elst W, Van Boxtel MP, Van Breukelen GJ, Jolles J: The Stroop color-word test: influence of age, sex, and education; and normative data for a large sample across the adult age range. Assessment 2006, 13:62-79.
36. Stinissen J, Willems P, Coetsier P, Hulsman WLL: Manual of the Dutch adaption of the Wechsler Adult Intelligence Scale (WAIS) [Handleiding bij de Nederlandstalige bewerking van de Wechsler Adult Intelligence Scale (W.A.I.S.)]. Lisse, the Netherlands: Swets & Zeitlinger; 1970.
37. Lezak MD, Howieson DB, Bigler ED, Tranel D: Neuropsychological assessment. 5th edition. New York: Oxford University Press; 2012.
38. Schagen S, Schmand B, de Sterke S, Lindeboom J: Amsterdam Short-Term Memory test: a new procedure for the detection of feigned memory deficits. J Clin Exp Neuropsychol 1997, 19:43-51.
39. Vercoulen JH, Bazelmans E, Swanink CM, Fennis JF, Galama JM, Jongen PJ, Hommes O, Van der Meer JW, Bleijenberg G: Physical activity in chronic fatigue syndrome: assessment and its role in fatigue. J Psychiatr Res 1997, 31:661-673.
40. van der Werf SP, Prins JB, Vercoulen JH, van der Meer JW, Bleijenberg G: Identifying physical activity patterns in chronic fatigue syndrome using actigraphic assessment. J Psychosom Res 2000, 49:373-379.
41. Lamers LM, McDonnell J, Stalmeier PF, Krabbe PF, Busschbach JJ: The Dutch tariff: results and arguments for an effective design for national EQ-5D valuation studies. Health Econ 2006, 15:1121-1132.
42. Hakkaart-van Roijen L: Handleiding Short Form-Health and Labour Questionnaire (SF-HLQ). Rotterdam: iMTA, Erasmus Universiteit; 2010.
43. Van Roijen L, Essink-Bot ML, Koopmanschap MA, Bonsel G, Rutten FF: Labor and health status in economic evaluation of health care. The Health and Labor Questionnaire. Int J Technol Assess Health Care 1996, 12:405-415.
44. Hakkaart-van Roijen L, Tan SS, Bouwmans CAM: Manual for cost research: methods and unit costs for economic evaluations in health care [Handleiding voor kostenonderzoek: methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg]. Diemen: College voor zorgverzekeringen; 2010.
45. Koopmanschap MA, Rutten FF, van Ineveld BM, van Roijen L: The friction cost method for measuring indirect costs of disease. J Health Econ 1995, 14:171-189.
46. Maruish ME: User's Manual for the SF-36v2 Health Survey. 3rd edition. Lincoln, RI: QualityMetric Incorporated; 2011.
47. Borm GF, Fransen J, Lemmens WA: A simple sample size formula for analysis of covariance in randomized clinical trials. J Clin Epidemiol 2007, 60:1234-1238.
48. Dattwyler RJ, Wormser GP, Rush TJ, Finkel MF, Schoen RT, Grunwaldt E, Franklin M, Hilton E, Bryant GL, Agger WA, Maladorno D: A comparison of two treatment regimens of ceftriaxone in late Lyme disease. Wien Klin Wochenschr 2005, 117:393-397.
49. Van Dam AP, Kuiper H, Vos K, Widjojokusumo A, de Jongh BM, Spanjaard L, Ramselaar AC, Kramer MD, Dankert J: Different genospecies of Borrelia burgdorferi are associated with distinct clinical manifestations of Lyme borreliosis. Clin Infect Dis 1993, 17:708-717.
50. Donta ST: Tetracycline therapy for chronic Lyme disease. Clin Infect Dis 1997, 25(Suppl 1):S52-S56.
51. Donta ST: Macrolide therapy of chronic Lyme Disease. Med Sci Monit 2003, 9:PI136-PI142.
52. Maurin M, Benoliel AM, Bongrand P, Raoult D: Phagolysosomal alkalinization and the bactericidal effect of antibiotics: the Coxiella burnetii paradigm. J Infect Dis 1992, 166:1097-1102.
53. Burrascano J: Diagnostic Hints and Treatment Guidelines for Lyme and Other Tick Borne Illnesses. [http://www.ilads.org/lyme/treatment-guideline.php]
54. Ware JEJ, Kosinski M, Keller SD: SF-36 Physical and Mental Health Summary Scales: a user's manual. Boston, MA: The Health Institute, New England Medical Center; 1994.
55. Cunningham WE, Nakazono TT, Tsai KL, Hays RD: Do differences in methods for constructing SF-36 physical and mental health summary measures change their associations with chronic medical conditions and utilization? Qual Life Res 2003, 12:1029-1035.
56. Farivar SS, Cunningham WE, Hays RD: Correlated physical and mental health summary scores for the SF-36 and SF-12 Health Survey, V.I. Health Qual Life Outcomes 2007, 5:54.
57. Hays RD, Morales LS: The RAND-36 measure of health-related quality of life. Ann Med 2001, 33:350-357.
58. Nortvedt MW, Riise T, Myhr KM, Nyland HI: Performance of the SF-36, SF-12, and RAND-36 summary scales in a multiple sclerosis population. Med Care 2000, 38:1022-1028.
59. Schmitz N, Kruse J: The SF-36 summary scores and their relation to mental disorders: physical functioning may affect performance of the summary scores. J Clin Epidemiol 2007, 60:163-170.
60. Simon GE, Revicki DA, Grothaus L, Vonkorff M: SF-36 summary scores: are physical and mental health truly distinct? Med Care 1998, 36:567-572.
61. Taft C, Karlsson J, Sullivan M: Do SF-36 summary component scores accurately summarize subscale scores? Qual Life Res 2001, 10:395-404.
62. Wilson D, Parsons J, Tucker G: The SF-36 summary scales: problems and solutions. Soz Praventivmed 2000, 45:239-246.